MED12 overexpression is a frequent event in castration-resistant prostate cancer.

@article{Shaikhibrahim2014MED12OI,
  title={MED12 overexpression is a frequent event in castration-resistant prostate cancer.},
  author={Zaki Shaikhibrahim and Anne Offermann and Martin Ulrich Braun and Roopika Menon and Isabella Syring and Michael Nowak and Rebecca Halbach and Wenzel Vogel and Christian Ruiz and Tobias Zellweger and Cyrill A. Rentsch and Maria Svensson and Ove Andr{\'e}n and Lukas Bubendorf and Saskia Biskup and Stefan Duensing and Jutta Kirfel and Sven Perner},
  journal={Endocrine-related cancer},
  year={2014},
  volume={21 4},
  pages={663-75}
}
In a recent effort to unravel the molecular basis of prostate cancer (PCa), Barbieri and colleagues using whole-exome sequencing identified a novel recurrently mutated gene, MED12, in 5.4% of primary PCa. MED12, encoding a subunit of the Mediator complex, is a transducer of Wnt/β-catenin signaling, linked to modulation of hedgehog signaling and to the regulation of transforming growth factor beta (TGFβ)-receptor signaling. Therefore, these studies prompted us to investigate the relevance of… CONTINUE READING